NASDAQ:VOR Vor Biopharma (VOR) Stock Price, News & Analysis $31.72 -1.68 (-5.03%) Closing price 04:00 PM EasternExtended Trading$31.74 +0.02 (+0.05%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vor Biopharma Stock (NASDAQ:VOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vor Biopharma alerts:Sign Up Key Stats Today's Range$31.26▼$33.2050-Day Range$27.24▼$48.7252-Week Range$2.62▼$65.80Volume423,069 shsAverage Volume468,751 shsMarket Capitalization$217.41 millionP/E RatioN/ADividend YieldN/APrice Target$113.83Consensus RatingHold Company Overview Vor Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability. The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Preclinical studies have demonstrated selective resistance of edited HSCs to CD33-directed therapies, allowing concurrent administration of anti-CD33 agents to eliminate malignant cells while preserving healthy hematopoiesis. In addition to VOR33, Vor maintains a discovery pipeline of follow-on candidates targeting other hematologic cancer antigens, as well as programs exploring combination strategies with existing immunotherapies. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vor Biopharma went public in 2021 and collaborates with leading academic medical centers and contract development organizations across the United States. The company is led by President and Chief Executive Officer Sean Nolan, whose previous experience includes senior leadership roles in immuno-oncology and cell therapy development. Vor’s scientific advisory board comprises experts in hematology, stem cell biology, and genome editing, supporting its mission to transform the treatment paradigm for blood cancer patients.AI Generated. May Contain Errors. Read More Vor Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVOR MarketRank™: Vor Biopharma scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingVor Biopharma has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialVor Biopharma has a consensus price target of $113.83, representing about 258.9% upside from its current price of $31.72.Amount of Analyst CoverageVor Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Vor Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vor Biopharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vor Biopharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted27.92% of the float of Vor Biopharma has been sold short.Short Interest Ratio / Days to CoverVor Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vor Biopharma has recently decreased by 94.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.92% of the float of Vor Biopharma has been sold short.Short Interest Ratio / Days to CoverVor Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vor Biopharma has recently decreased by 94.44%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.34 News SentimentVor Biopharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.37 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Vor Biopharma this week, compared to 3 articles on an average week.Search Interest31 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 182% compared to the previous 30 days.MarketBeat Follows5 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,773,312.00 in company stock.Percentage Held by InsidersOnly 0.45% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VOR Stock News HeadlinesInsider Selling: Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells 27,624 Shares of StockOctober 9 at 5:34 AM | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $54,866.00 in StockOctober 4, 2025 | insidertrades.comBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.October 9 at 2:00 AM | Crypto 101 Media (Ad)Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,805 SharesSeptember 16, 2025 | insidertrades.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 350,000 Shares of StockSeptember 11, 2025 | insidertrades.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comVor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46September 30, 2025 | msn.comVor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025September 29, 2025 | globenewswire.comSee More Headlines VOR Stock Analysis - Frequently Asked Questions How have VOR shares performed this year? Vor Biopharma's stock was trading at $21.20 on January 1st, 2025. Since then, VOR shares have increased by 49.6% and is now trading at $31.72. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NASDAQ:VOR) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by $32.20. When did Vor Biopharma's stock split? Vor Biopharma shares reverse split on Thursday, September 18th 2025.The 1-20 reverse split was announced on Thursday, September 18th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2025Today10/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Biological Products, Except Diagnostic Substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VOR Previous SymbolNASDAQ:VOR CIK1817229 WebN/A Phone(617) 655-6580FaxN/AEmployees140Year Founded2016Price Target and Rating Average Price Target for Vor Biopharma$113.83 High Price Target$280.00 Low Price Target$8.00 Potential Upside/Downside+258.9%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares6,854,000Free Float6,823,000Market Cap$217.41 million OptionableN/A Beta2.07 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VOR) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.